The potential for AI development to transform global healthcare culture from one of 'reactive disaster management' to one of 'prevention and early intervention' through predictive systems has become clear over the last ten years. The potential benefits remain compelling1,2, with the healthcare AI market forecast recently to reach US$51.3 billion by 20273.
Possible applications and developments include:
- Automation of medical imaging analysis4.
- Identification of molecular biomarkers for disease, without biopsies, from simple fluid samples5.
- Predictive health analytics (PHA) powering AI-based home monitoring systems6,7 for terminal and high-risk patients (a group representing just 5% of patients but 60% of healthcare costs in the US8).
- Drug discovery, including prediction, design and drug-target interaction (DTI) phases9.
- Machine-driven analysis and logistical strategies for co-morbidities in chronic disease management (CDM)10.
- Clinical trials for the identification of suitable candidates11; for the identification of biologics12 (large biological molecules) that may contribute to drug evolution for trials; and for ROI analysis13.
- New machine learning insights and applications related to epidemiology, including statistical prediction models14 and containment15.
- The use of AI input for virtual, augmented and mixed reality (VAMR) in healthcare research, monitoring and palliative care16, as well as for adding an 'informed' VR layer to telesurgery procedures17.
- AI in genomics research18,19.
- AI-informed chatbots and engagement systems in the telehealth sector20.
Systems and applications like this require access to patient data — perhaps the most politically and socially volatile topic in debates over the future of data science and machine learning. Since this represents a major impediment to progress21, and since it tends to dominate the discourse, let's examine the obstacles, and consider possible remedies.